ST8SIA2 and cancer: Last, our early TCR discovery efforts indicate that the peptide derived from ST8SIA2 is suitably immunogenic, suggesting the absence of strong tolerogenic mechanisms, and aligning with larger literature on cancer-specific expression of ST8SIA2, and our own bioinformatics analysis on its presentation in cancers and normal tissues.